A gener8tor portfolio company

SAFE Round Scenarios

Ambient Intelligence is raising $500k to $3M on a $15M post-money SAFE, modeled end to end.

$15M
post-money cap
$500k–$3M
raise range
20%
discount
≈$400k
prior funding
3.3–20%
sold to round
Shared with the gener8tor team. Figures are the company's own seed model and SAFE math follows the YC post-money SAFE; illustrative and not an offer to sell securities.
The instrument

A post-money SAFE

The market-standard instrument at this stage: fast to close, low legal cost on both sides, and it converts to equity at the next priced round. The post-money structure fixes the cap against total SAFE money raised, so each investor knows their exact ownership at close.

Type
Post-money SAFE (YC standard)
Valuation cap
$15,000,000 post-money
Discount
20%
Conversion
At the next priced equity round
MFN
Most-favored-nation on later SAFEs
Pro-rata
Side letter for checks ≥ $250k
Scenarios

$500k to $3M on one cap

On a post-money SAFE the cap is the post-money valuation, so the share sold to this round is the raise divided by the $15M cap and the implied pre-money is the cap minus the new money. Figures assume the cap binds at conversion (a priced round above $18.8M, where the cap beats the 20% discount).

Raise (SAFE)Sold to roundImplied pre-moneyPost-moneyShare sold
$500k3.33%$14.5M$15M
$1M6.67%$14M$15M
$1.5M10.00%$13.5M$15M
$2M13.33%$13M$15M
$2.5M16.67%$12.5M$15M
$3MTARGET20.00%$12M$15M

Bar scaled ×5 for visibility. Pre-money = cap − new money, the defining property of a post-money SAFE.

Funding to date

About $400k raised so far

This SAFE round is opening now — there are no commitments to it yet. Behind the company sits about $398k in prior funding and grants. Of that, only $150k is dilutive (the ODAT grant takes no equity); those prior gener8tor and angel SAFEs are carried into the cap table below.

ODAT grant
$248k
Non-dilutive · funds the MOH pilot
gener8tor
$100k
Accelerator · prior SAFE
Angel
$50k
Early check · prior SAFE
Conversion mechanics

What founders keep after conversion

Combining the $150k of prior SAFEs with each new-raise scenario — all on the $15M cap — gives the aggregate SAFE ownership at conversion, before any new priced-round money. Founders and existing equity hold the rest.

New raiseTotal SAFE moneySAFE holders ownFounders + existing
$500k$650k4.33%95.67%
$1M$1.1M7.67%92.33%
$1.5M$1.6M11.00%89.00%
$2M$2.1M14.33%85.67%
$2.5M$2.6M17.67%82.33%
$3M$3.1M21.00%79.00%
Cap vs. discount
Investors convert at the better of the $15M cap or a 20% discount to the priced round. Above a $18.8M priced valuation the cap wins; below it, the discount does.
Worked example
At a $20M pre-money Series A, the 20% discount implies $16M; the $15M cap is lower, so the cap binds and SAFE holders convert as if priced at $15M.
Option pool
A priced round typically carves a ~10% option pool. Applied to the $3M case, founders + existing land near 71% before the new priced money — still firmly in control.
Use of funds

What each tranche unlocks

The raise is milestone-driven. Each tranche maps to active work already in motion — the round accelerates a de-risking sequence rather than starting one.

$500k
Unblock the pilot, reach clinical data
Close out PCB serials and the first production run with EI Microcircuits, ship the hardware watchdog cold-reset, and complete the Mount Olivet / MOH 36-unit deployment. Outcome: first real-world deployment data.
$1.5M
Pilot scale + regulatory + IP
Fund the FDA De Novo pathway work and reimbursement strategy, file the PCT on provisional 63/740,576, and ship the Ella nurse dashboard. Outcome: a defensible regulatory + IP position behind live pilots.
$3.0M
Full seed runway to De Novo + multi-site
Carry the company through De Novo submission prep, multi-site expansion beyond the first pilot, and the core team build. Outcome: a priced-round-ready company with regulatory, clinical, and commercial proof.
Valuation basis

Why $15M

The $15M cap is our seed thesis, anchored to a milestone-driven de-risking model — not an independent market appraisal. The traction below is real and verifiable; the comparable-company set is illustrative and not used to assert the number.

Device
Dual-AoP radar validated; contactless vitals (HR + respiration) emitting; fall + long-lie detection; 24h endurance bench passed (0 drops).
Pilot
Mount Olivet pilot approved (Dr. Roger White); MOH 36-unit deployment in motion; manufacturing partner signed (EI Microcircuits).
Regulatory & cloud
QMS system-of-record live (QMSR in force); HIPAA determination complete; AmbientCloud live across 13 stacks.
IP
Provisional patent filed (63/740,576); PCT international filing in progress.
Non-dilutive & research
ODAT grant $248k secured; NIH STTR submitted (1R41AG097177), A1 resubmission under review.
Recognition
MN Cup 2026 semifinalist (Impact Ventures, 92 of 1,262); gener8tor accelerator.
Contact

Let's talk terms

Happy to walk gener8tor through any scenario, share the data room, or tailor the cap and discount to a lead. Reach us at bri@ambienthealthgroup.com.

Email us →Data room

Figures are the company's own seed model, anchored to internal milestones. SAFE math follows the YC post-money SAFE; scenarios assume the $15M cap binds at conversion and that prior SAFEs convert on the same cap. Comparable-company data is illustrative and unverified. This page is for discussion with gener8tor and is not an offer to sell or a solicitation to buy securities. Last updated 2026-06-26.